A Game-Changing Drug for Pancreatic Cancer Just Got FDA Approval
In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on gizmodo.com — the content belongs to Gizmodo.